Akero Therapeutics Inc diskutieren
Akero Therapeutics Inc
WKN: A2PLNP / Symbol: AKRO / Name: Akero Therapeutics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
46,97 €
0,47 %
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $65.00 price target on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at HC Wainwright from $50.00 to $72.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at Citigroup Inc. from $65.00 to $80.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at Morgan Stanley from $46.00 to $96.00. They now have an "overweight" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at UBS Group AG from $42.00 to $109.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at HC Wainwright from $72.00 to $75.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "overweight" rating re-affirmed by analysts at Morgan Stanley.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target lowered by analysts at Citigroup Inc. from $80.00 to $78.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at Bank of America Co. from $63.00 to $64.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) is now covered by analysts at TD Cowen. They set a "buy" rating and a $76.00 price target on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics (NASDAQ:AKRO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $72.00 price target on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics (NASDAQ:AKRO) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics (NASDAQ:AKRO) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Ratings data for AKRO provided by MarketBeat
Neueste Beiträge
Cowen_Inc in Rhythm Pharmaceuticals diskutieren